Nektar Therapeutics Debt Securities, Available-for-sale
Nektar Therapeutics (NKTR) had Debt Securities, Available-for-sale of $1.01 billion as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-14
- 2026-06-30: Debt Securities, Available-for-sale $1.01B.
- 2026-03-31: Debt Securities, Available-for-sale $694.16M.
- 2025-12-31: Debt Securities, Available-for-sale $216.50M.
- 2025-09-30: Debt Securities, Available-for-sale $219.93M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $1.01B 10-Q · filed 2026-08-14 |
| 2026-03-31 | $694.16M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $216.50M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $219.93M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $136.77M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $182.55M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $229.25M 10-K · filed 2026-03-13 |
| 2023-12-31 | $294.12M 10-K · filed 2025-03-14 |
| 2022-12-31 | $427.73M 10-K · filed 2024-03-05 |
| 2021-12-31 | $762.63M 10-K · filed 2023-02-28 |
| 2020-12-31 | $1.00B 10-K · filed 2022-03-01 |
| 2019-12-31 | $1.51B 10-K · filed 2020-02-28 |
| 2019-09-30 | $1.65B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.72B 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.79B 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.80B 10-K · filed 2020-02-28 |
| 2018-09-30 | $1.94B 10-Q · filed 2018-11-08 |
| 2017-12-31 | $347.33M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |